Hematology Practice Questions

Q: What is the first change of improvement noted after iron therapy is initiated?

Decreased irritability. **Explanation:** The clinical response to iron therapy in Iron Deficiency Anemia (IDA) follows a highly predictable chronological sequence. **1. Why "Decreased Irritability" is correct:** The earliest response to iron therapy is **subjective clinical improvement**, specifically a decrease in irritability and an increase in appetite. This occurs within **12 to 24 hours** of initiating therapy. This rapid change happens because iron is a crucial cofactor for several enzymes in the central nervous system (such as monoamine oxidase) and cellular metabolism (cytochromes). These enzymes are replenished long before new red blood cells are produced. **2. Analysis of Incorrect Options:** * **B. Reticulocytosis:** This is the first **objective hematological** sign of improvement. It typically begins within 48–72 hours and peaks between 5 to 10 days after starting therapy. * **C. Increase in serum iron levels:** While serum iron may fluctuate after a dose, it is not used as a reliable marker of early therapeutic response compared to clinical or reticulocyte changes. * **D. Replenishment of iron stores:** This is the **final** stage of therapy. Hemoglobin levels usually normalize within 1–2 months, but therapy must be continued for an additional 3–4 months to replenish ferritin (iron stores). **High-Yield Clinical Pearls for NEET-PG:** * **Sequence of Improvement:** Subjective/Enzymatic (12-24h) → Reticulocytosis (3-7 days) → Increase in Hemoglobin (begins in 1 week, normalizes by 2 months) → Storage/Ferritin (3-6 months). * **Oral Dose (Pediatrics):** 3–6 mg/kg/day of elemental iron. * **Best Absorption:** Iron is best absorbed on an empty stomach with Vitamin C (ascorbic acid), which maintains iron in the ferrous ($Fe^{2+}$) state.

Q: A 7-year-old boy presented with sudden onset petechiae and purpura. There was a history of upper respiratory tract infection 2 weeks prior. On examination, there was no hepatosplenomegaly. What is the most probable diagnosis?

Idiopathic Thrombocytopenic Purpura. ### Explanation The clinical presentation is classic for **Immune Thrombocytopenic Purpura (ITP)**, formerly known as Idiopathic Thrombocytopenic Purpura. **Why Option C is Correct:** ITP in children typically presents in the **2–8 year age group** with a sudden onset of isolated thrombocytopenia (petechiae, purpura, and bruising). A key diagnostic feature is a **preceding viral illness** (URTI or exanthem) occurring 1–3 weeks prior. Crucially, the absence of hepatosplenomegaly and lymphadenopathy points toward a diagnosis where only the platelet lineage is affected, rather than a systemic or bone marrow process. **Why Other Options are Incorrect:** * **A. Acute Lymphoblastic Leukemia (ALL):** While ALL presents with petechiae, it is usually accompanied by systemic signs like fever, bone pain, and physical findings like **hepatosplenomegaly** or lymphadenopathy. * **B. Acute Viral Infection:** While some viruses (like Dengue) cause thrombocytopenia, the 2-week lag period and the "sudden onset" of skin bleeds in an otherwise well-appearing child specifically favor the post-viral immune-mediated destruction seen in ITP. * **D. Aplastic Anemia:** This involves pancytopenia. Patients would typically present with symptoms of anemia (pallor, fatigue) and increased susceptibility to infections (neutropenia), which are absent here. **Clinical Pearls for NEET-PG:** * **Pathogenesis:** Type II hypersensitivity reaction where IgG autoantibodies are directed against platelet surface glycoproteins (**GpIIb/IIIa**). * **Bone Marrow:** If performed (to rule out leukemia), it shows **increased megakaryocytes**. * **Management:** Most childhood cases are self-limiting. If treatment is required (platelets <20,000/mm³ or significant bleeding), **IVIG** or **Corticosteroids** are first-line. * **Rule of Thumb:** Isolated thrombocytopenia + No Splenomegaly + Preceding URTI = ITP.

Q: Macrocytic anemia in children is produced by all of the following except?

Copper deficiency. **Explanation:** The correct answer is **Copper deficiency** because it typically presents as a **microcytic, hypochromic anemia** (mimicking iron deficiency) or a normocytic anemia, often accompanied by neutropenia. Copper is a vital cofactor for *hephaestin* and *ceruloplasmin*, enzymes required for iron transport and utilization. Its deficiency leads to impaired iron incorporation into hemoglobin, resulting in small red blood cells rather than large ones. **Analysis of other options:** * **Thiamine deficiency (Option A):** Specifically, **Thiamine-Responsive Megaloblastic Anemia (TRMA)** or Rogers Syndrome is a rare genetic disorder characterized by megaloblastic (macrocytic) anemia, non-type 1 diabetes, and sensorineural deafness. * **Orotic aciduria (Option B):** This is an autosomal recessive disorder of pyrimidine synthesis. The deficiency of UMP synthase leads to a failure in DNA synthesis, resulting in a **megaloblastic (macrocytic) anemia** that does not respond to Vitamin B12 or Folic acid. * **Liver disease (Option C):** Chronic liver disease causes macrocytosis through several mechanisms, including increased lipid deposition on the RBC membrane (target cells) and altered cholesterol metabolism, leading to an increased Mean Corpuscular Volume (MCV). **High-Yield Clinical Pearls for NEET-PG:** 1. **Copper Deficiency Hallmark:** Look for the combination of **anemia + neutropenia** in a patient on long-term TPN or following gastric bypass surgery. 2. **Bone Marrow Finding:** Copper deficiency often shows **ringed sideroblasts** and cytoplasmic vacuolization in myeloid precursors, which can be mistaken for Myelodysplastic Syndrome (MDS). 3. **Macrocytic Anemia Classification:** Always differentiate between **Megaloblastic** (DNA synthesis defect: B12/Folate deficiency, Orotic aciduria) and **Non-megaloblastic** (Liver disease, Hypothyroidism, Diamond-Blackfan anemia).

Q: A 2-year-old child presents with short stature and cafe-au-lait spots. Bone marrow aspiration yields a little material and mostly containing fat. What is your diagnosis?

Fanconi anemia. ### Explanation **Correct Answer: A. Fanconi Anemia** **Reasoning:** The clinical triad of **short stature**, **café-au-lait spots**, and **aplastic anemia** (suggested by the "dry tap" or fat-rich bone marrow) is classic for **Fanconi Anemia (FA)**. FA is the most common cause of inherited bone marrow failure. It is an autosomal recessive (mostly) DNA repair defect. * **Physical Findings:** Short stature, skin hyperpigmentation (café-au-lait spots), and skeletal anomalies (especially **absent/hypoplastic thumb** or radius). * **Hematology:** Progressive pancytopenia usually manifests between ages 2 and 10. The bone marrow biopsy typically shows **hypocellularity with fatty replacement**, as described in the question. **Why other options are incorrect:** * **B. Dyskeratosis Congenita:** While it also causes inherited bone marrow failure, it is characterized by a specific clinical triad: **abnormal skin pigmentation (reticular), nail dystrophy, and oral leukoplakia**. * **C. Tuberous Sclerosis:** Presents with café-au-lait spots and skin lesions (ash-leaf spots, adenoma sebaceum), but it is a neurocutaneous syndrome associated with seizures and tumors (hamartomas), not bone marrow failure. * **D. Osteogenesis Imperfecta:** Characterized by bone fragility, blue sclera, and hearing loss; it does not present with aplastic anemia or café-au-lait spots. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Test:** Chromosomal breakage analysis using **Diepoxybutane (DEB)** or Mitomycin C. * **Malignancy Risk:** Patients have a significantly increased risk of **AML** and squamous cell carcinomas (head, neck, and anogenital). * **Most common skeletal deformity:** Thumb and radial ray defects. * **Treatment of choice:** Hematopoietic stem cell transplant (HSCT).

Q: A 7-year-old boy has severe microcytic anemia due to beta-thalassemia major (homozygous). He requires frequent blood transfusions to prevent skeletal and developmental complications. Which of the following medications is also indicated in the treatment of patients requiring frequent blood transfusions?

Desferrioxamine. **Explanation:** The patient has **Beta-Thalassemia Major**, a condition characterized by ineffective erythropoiesis and severe anemia requiring lifelong regular blood transfusions. The primary complication of chronic transfusion therapy is **Secondary Hemochromatosis (Iron Overload)**. Since the human body lacks an active mechanism to excrete excess iron, each unit of blood (containing ~200mg of iron) contributes to systemic deposition, leading to multi-organ damage (heart, liver, and endocrine glands) [2]. **Why Desferrioxamine is correct:** **Desferrioxamine** is a high-affinity **iron-chelating agent**. It binds to free iron and ferritin-bound iron to form ferrioxamine, which is then excreted via the kidneys and bile. It is indicated when serum ferritin levels exceed 1,000 ng/mL or after the patient has received approximately 10–20 transfusions. **Why other options are incorrect:** * **Oral calcium supplements:** While patients with thalassemia may develop hypoparathyroidism or osteoporosis due to iron deposition, calcium is not a primary treatment for transfusion-related complications. * **Fresh frozen plasma (FFP):** FFP is used to replace clotting factors in coagulopathies; it has no role in treating thalassemia or iron overload. * **Penicillamine:** This is a chelating agent used primarily for **Copper** (Wilson’s disease) and sometimes in rheumatoid arthritis or cystinuria, not for iron overload [1]. **NEET-PG High-Yield Pearls:** * **Routes of Administration:** Desferrioxamine is given SC/IV (poor oral bioavailability). **Deferasirox** and **Deferiprone** are preferred oral alternatives. * **Side Effects:** Desferrioxamine can cause ototoxicity (high-frequency hearing loss) and retinal toxicity. * **Cause of Death:** The most common cause of death in inadequately chelated Thalassemia Major patients is **Heart Failure** (due to siderotic cardiomyopathy).

Q: A 7-year-old child is brought to the clinic with complaints of fatigue and poor concentration. The mother reports that the child has been eating non-food items such as chalk and soil for the past few months. A peripheral blood smear image shows microcytic, hypochromic red blood cells. Which of the following is the most likely diagnosis?

Iron deficiency anemia. ***Iron deficiency anemia*** - The patient's history of **pica** (craving and eating non-food items like chalk and soil) is a classic clinical sign of iron deficiency. - The peripheral blood smear confirms this diagnosis by showing **microcytic** (small) and **hypochromic** (pale) red blood cells, which result from impaired hemoglobin synthesis due to a lack of iron. *Vitamin B12 deficiency* - This condition causes **macrocytic anemia**, where red blood cells are larger than normal (high MCV), which is the opposite of the findings in this case. - Peripheral smear findings in B12 deficiency typically include **macro-ovalocytes** and **hypersegmented neutrophils**, neither of which is described or shown. *Thalassemia major* - Although thalassemia causes a **microcytic, hypochromic anemia**, it is a genetic disorder that typically presents in infancy with severe symptoms like failure to thrive and massive **hepatosplenomegaly**. - Pica is not a characteristic feature of thalassemia; it is strongly associated with iron deficiency anemia. *Lead poisoning* - Lead poisoning can cause microcytic anemia, but a key finding on the peripheral smear is **basophilic stippling**, which is not the prominent feature here. - While pica can be a risk factor for lead ingestion, pica itself is a more direct and classic symptom of underlying **iron deficiency**.

Q: A child with progressive pallor and bone pain has an elevated HbS based on the HPLC report. Which is the best treatment to manage hemolysis in this patient?

Voxelotor. ***Voxelotor*** - It is a **hemoglobin polymerization inhibitor** that stabilizes the oxygenated form of red blood cells, preventing **sickling** and subsequent hemolytic anemia, thereby directly managing the hemolysis. - It significantly improves **hemoglobin levels** and reduces markers of hemolysis, such as **indirect bilirubin** and **reticulocyte count**. *Hydroxyurea* - Its primary mechanism is inducing the production of **fetal hemoglobin (HbF)**, thereby diluting the concentration of HbS and *indirectly* reducing hemolysis over time. - Although crucial for managing **vaso-occlusive crises** (VOCs), it is not as direct an anti-hemolytic agent as Voxelotor. *Azacytidine* - This is a **DNA methyltransferase inhibitor**, primarily used in high-risk **Myelodysplastic Syndrome (MDS)** and Acute Myeloid Leukemia (AML). - While it can induce HbF like Hydroxyurea, it is not a standard or approved frontline treatment for the routine management of Sickle Cell Disease (SCD). *Bortezomib* - This drug is a **proteasome inhibitor** used exclusively in the treatment of **Multiple Myeloma** and certain related plasma cell dyscrasias. - It has no therapeutic role or clinical indication in the specific management of hemolysis or the underlying pathophysiology of SCD.

Q: A young boy presented with petechiae and his platelet count was 10,000/cu mm. Bone marrow aspirate revealed normal cellularity with megakaryocyte hyperplasia. Most appropriate initial therapy?

IVIG. ***IVIG*** - The presentation (young patient, **petechiae**, extremely low platelet count of 10,000/cu mm, and **megakaryocyte hyperplasia** in bone marrow) is classic for **Immune Thrombocytopenia (ITP)**. - Given the severe thrombocytopenia (platelets <20,000/cu mm) and active bleeding risk (petechiae), the initial treatment of choice is typically **IVIG (Intravenous Immunoglobulin)** or corticosteroids to rapidly increase the platelet count. *Aspirin* - **Aspirin** is an antiplatelet agent that **inhibits platelet aggregation**; it is strictly contraindicated in severe thrombocytopenia like ITP as it would increase the risk of hemorrhage. - It is used for pain relief or secondary prevention of cardiovascular events, not for treating low platelet counts. *Bone Marrow Transplant* - **Bone marrow transplant** is a radical and highly risky procedure reserved for refractory, life-threatening hematological malignancies or severe aplastic anemia, or failed therapy for ITP. - It is never the appropriate **initial therapy** for acute ITP, which is predominantly an autoimmune disorder of peripheral platelet destruction. *Methotrexate* - **Methotrexate** is an immunosuppressive drug used typically in chronic inflammatory conditions (like rheumatoid arthritis) or malignancies. - It is considered a second or third-line treatment option, or part of a more aggressive immunosuppression regimen, for ITP that has failed initial therapy (steroids/IVIG), not the immediate first choice.

Question 1

What is the first change of improvement noted after iron therapy is initiated?

Accepted Answer

Decreased irritability

Answer

Reticulocytosis

Answer

Increase in serum iron levels

Answer

Replenishment of iron stores

Question 2

A 7-year-old boy presented with sudden onset petechiae and purpura. There was a history of upper respiratory tract infection 2 weeks prior. On examination, there was no hepatosplenomegaly. What is the most probable diagnosis?

Accepted Answer

Idiopathic Thrombocytopenic Purpura

Answer

Acute Lymphoblastic Leukemia

Answer

Acute viral infection

Answer

Aplastic Anemia

Question 3

A 20-month-old female child presents for a routine check-up. A complete blood count (CBC) reveals moderate neutropenia, but the child appears healthy, eats well, and is within expected developmental parameters for her age and sex. Other blood count parameters are within the normal range for her age. The family history is unremarkable. Repeat CBCs after one and two weeks show persistent neutropenia. Bone marrow examination is normal. What is the next best step in management?

Accepted Answer

Adopt a 'watch and wait' strategy

Answer

Administer corticosteroids

Answer

Administer multivitamins

Answer

Start antibiotics to prevent infection

Question 4

Macrocytic anemia in children is produced by all of the following except?

Accepted Answer

Copper deficiency

Answer

Thiamine deficiency

Answer

Orotic aciduria

Answer

Liver disease

Question 5

A 5-year-old boy presents with petechial spots that appeared overnight. Two weeks prior, he experienced abdominal pain. There is no hepatosplenomegaly. What is the most likely diagnosis?

Accepted Answer

Idiopathic thrombocytopenic purpura

Answer

Acute lymphoblastic leukemia

Answer

Aplastic anemia

Answer

Acute viral infection

Question 6

A 2-year-old child presents with short stature and cafe-au-lait spots. Bone marrow aspiration yields a little material and mostly containing fat. What is your diagnosis?

Accepted Answer

Fanconi anemia

Answer

Dyskeratosis congenita

Answer

Tuberous sclerosis

Answer

Osteogenesis imperfecta

Question 7

A 7-year-old boy has severe microcytic anemia due to beta-thalassemia major (homozygous). He requires frequent blood transfusions to prevent skeletal and developmental complications. Which of the following medications is also indicated in the treatment of patients requiring frequent blood transfusions?

Accepted Answer

Desferrioxamine

Answer

Oral calcium supplements

Answer

Fresh frozen plasma (FFP)

Answer

Penicillamine

Question 8

A 7-year-old child is brought to the clinic with complaints of fatigue and poor concentration. The mother reports that the child has been eating non-food items such as chalk and soil for the past few months. A peripheral blood smear image shows microcytic, hypochromic red blood cells. Which of the following is the most likely diagnosis?

Accepted Answer

Iron deficiency anemia

Answer

Lead poisoning

Answer

Thalassemia major

Answer

Vitamin B12 deficiency

Question 9

A child with progressive pallor and bone pain has an elevated HbS based on the HPLC report. Which is the best treatment to manage hemolysis in this patient?

Accepted Answer

Voxelotor

Answer

Azacytidine

Answer

Hydroxyurea

Answer

Bortezomib

Question 10

A young boy presented with petechiae and his platelet count was 10,000/cu mm. Bone marrow aspirate revealed normal cellularity with megakaryocyte hyperplasia. Most appropriate initial therapy?

Accepted Answer

IVIG

Answer

Bone Marrow Transplant

Answer

Methotrexate

Answer

Aspirin

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?